BioSpace News Archive

Drug Development

ASCO: BMS’ Opdivo Challenges Seagen’s Adcetris with Phase III Win

Data from a new head-to-head study showed BMS’ Opdivo induced better progression-free survival among Hodgkin’s lymphoma patients than Seagen’s Adcetris.

June 5, 2023
·
2 min read
·
Tristan Manalac
Drug Development

ASCO: French Pharma’s Drug Slows Tumors in Brain Cancer Patients

Servier Pharmaceuticals’ Vorasidenib, acquired from Agios in a $1.8 billion deal, slowed the growth of a certain type of low-grade glioma by 61% in a Phase III trial.

June 5, 2023
·
3 min read
·
Heather McKenzie
Drug Development

ASCO: AstraZeneca Posts Strong Survival Data for Tagrisso in NSCLC Patients

After five years of follow-up, AstraZeneca’s Tagrisso reduces the risk of death by 51% as compared with placebo in EGFR-mutated NSCLC patients, according to Phase III ADAURA trial results.

June 5, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Akero’s NASH Candidate Clears Phase IIb, Cuts Liver Fat by up to 65%

Non-alcoholic steatohepatitis patients treated with the company’s efruxifermin saw significant improvements in liver fat and biomarkers of liver damage, fibrosis and cardiometabolic health.

June 5, 2023
·
4 min read
·
Tristan Manalac
Drug Development

ASCO: AstraZeneca Imfinzi-Lynparza Shows Benefit in Phase III Ovarian Cancer Study

The combination therapy was added to standard chemotherapy and lowered the risk of progression or death by 37% in newly diagnosed patients with advanced ovarian cancer without BRCA mutations.

June 5, 2023
·
2 min read
·
Lisa Munger
Genetown

ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes

ERYTECH Pharma announced that Akkadian Partners has initiated legal proceedings to obtain the postponement of the vote on the merger with Pherecydes at the Annual General Meeting on June 23.

June 5, 2023
·
1 min read
BioInvent to Present at Jefferies Healthcare Conference on June 8

BioInvent International announces it will present the company at the Jefferies Healthcare Conference, taking place June 7-9 in New York.

June 5, 2023
·
2 min read
The University of Oxford and Selvita Collaborate to Advance Potential Therapeutics for Parkinson’s Disease

The University of Oxford and Selvita, one of the largest contract research organizations in Europe, announced an integrated drug discovery collaboration in the area of Parkinson’s disease.

June 5, 2023
·
4 min read
ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced an equity investment round of €255 million led by Temasek with participation from BlackRock Alternatives1,Qatar Investment Authority, Nextech2, ATHOS and Carbyne.

June 5, 2023
·
7 min read
Drug Development

CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody Visugromab in Combination with Nivolumab at ASCO 2023

CatalYm announced first Phase 2a data from its ongoing GDFather-2 trial at the American Society of Clinical Oncology Annual Meeting 2023 in Chicago, Illinois.

June 5, 2023
·
5 min read